Results published in Cell Systems demonstrate the Lung-Chip’s new life-like ‘smoking’ component to evaluate the effects of smoke exposure and e-cigarettes in patients with chronic lung diseases
Collaborative R&D to focus on innovation for patient-driven advances in cancer treatment
Joint capabilities seek to establish Organs-on-Chips as a new preclinical testing platform
Series B Funding Round Totals $45 Million from Syndicate of Life Sciences and Technology Investors
Under the terms of the agreement, Seres and Emulate will work to further advance Emulate’s Intestine-Chip platform, a micro-engineered, living-tissue-based system that models the human intestine.
Proceeds will accelerate launch of products and applications so that the ‘Human Emulation System’ operates in the hands of researchers and product developers.
Company establishes strategic collaborations to use Organs-on-Chips technology for developing more effective and safer drugs, consumer products and foods; improving patient well-being through new precision medicine and personal health applications. Ribbon-cutting ceremony to take place today with state and local officials, and the life sciences community.